Precision Oncology
We are setting the standard
At Variantyx, we are setting the standard of genome analysis. We are leading the way in precision oncology by offering the most comprehensive test available for cancer treatment and management. We pair multiple analytic technologies plus tumor versus matched normal comparison with our advanced interpretation platform to deliver a uniquely actionable, personalized report.
We additionally offer the most comprehensive diagnostic testing clinically available for hereditary cancer predisposition. With thorough interrogation of the genome, we have the ability to detect clinically relevant sequence and structural variant types from one sample. A single, unified clinical report is generated through variant evaluation performed by clinical experts.
Using our methodology’s superior analytical and clinical validity, we are providing better overall performance and the most complete assessment of hereditary cancer risk. All with a single test, and a single cost.
We use three technologies for optimal detection
Combining whole genome sequencing for comprehensive and consistent coverage, whole exome sequencing for deep coverage and whole transcriptome RNA sequencing for broad detection of fusions and rearrangements, our analysis of solid tumors provides a comprehensive and accurate genomic profile.
Tumor versus matched normal comparison enables accurate and informative profiling of germline variants with FDA-approved therapies, onco-pharmacogenomic star alleles and tumor mutational burden (TMB).
Our methodology detects variants missed by others
Genetic disorders are caused by a wide variety of DNA changes. Comprehensive detection of all major clinically relevant variant types requires the right technology. PCR-free whole genome sequencing (WGS) generates uniform coverage of >98% of the patient’s DNA. Compare that to PCR-based panel and exome technologies that remove and skew data, generating fragmented coverage of only 1-2% of the patient’s DNA.
Pairing WGS with our Genomic Intelligence® proprietary analytical software provides the most comprehensive variant detection available, sequencing and analyzing the entire gene. In comparison, most other hereditary cancer tests only sequence and analyze targeted regions of the gene, typically exons and selected intronic regions.
OncoAlly® Solid Tumor Analysis Hereditary cancer analyses
OncoAlly® hereditary cancer analyses focus on pre-curated sets of indication-relevant genes. With the full underlying genome data always available, we have the flexibility to add newly associated genes at any time.
